Search clinical trials for: SCB-2019 with Alum adjuvant

Total 862 results

Clover Biopharmaceuticals AUS Pty Ltd

Completed

SCB-2019 as COVID-19 Vaccine

COVID-19

Australia
Clover Biopharmaceuticals AUS Pty Ltd
International Vaccine Institute; Coalition for Epidemic Preparedness Innovations

Completed

A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)

COVID-19

Colombia, Belgium, Brazil, Philippines, South Africa
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults

COVID-19

South Africa
Clover Biopharmaceuticals AUS Pty Ltd

Terminated

Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases (COVID-19)

COVID-19

Ukraine
Sanofi Pasteur, a Sanofi Company

Completed

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects (FBP00004)

Healthy Volunteers | Influenza Immunisation

United States
SK Bioscience Co., Ltd.

Completed

Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
SK Bioscience Co., Ltd.
Coalition for Epidemic Preparedness Innovations

Completed

Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
Tehran University of Medical Sciences
Pasteur Institute of Iran, Tehran, Iran; Razi Vaccine and Serum Research Institute and other collaborators

Completed

Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0)

Healthy

Iran, Islamic Republic of
Tehran University of Medical Sciences
Pasteur Institute of Iran, Tehran, Iran; Razi Vaccine and Serum Research Institute and other collaborators

Completed

Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin

Healthy

Iran, Islamic Republic of
Madhu Chhanda Choudhary
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy (NETI)

HIV Infections

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (DPIV-001)

Dengue Fever

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (DPIV-002)

Dengue Fever

Puerto Rico
Jiangsu Province Centers for Disease Control and...
Bejing Vigoo Biological Co., LTD

Completed

A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children

EV71-associated Disease

China
NovaDigm Therapeutics, Inc.
United States Department of Defense

Completed

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

Candidiasis | Staphylococcal Infections | Yeast Infections

United States
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.

COVID-19

Australia
Pfizer
Valneva Austria GmbH

Completed

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Lyme Borreliosis, Nervous System

Belgium, United States
Clover Biopharmaceuticals AUS Pty Ltd

Withdrawn

Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age

COVID-19

Colombia
Medical University of Vienna
Allergy Centre Vienna West

Unknown

Immune Response of Individuals Vaccinated With Hypoallergenic Derivatives of the Major Birch Pollen Allergen, Bet v 1

Allergy

Austria
U.S. Army Medical Research and Development Command

Completed

TDENV PIV and LAV Dengue Prime-boost Strategy

Dengue

United States
D'Or Institute for Research and Education
Bill and Melinda Gates Foundation

Active, not recruiting

Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes.

COVID-19

Brazil
Anderson Clinical Research
Ligand Pharmaceuticals

Completed

A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi
D'Or Institute for Research and Education
Bill and Melinda Gates Foundation; University of Oxford

Not yet recruiting

An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens

COVID-19

Brazil
PATH Vaccine Solutions

Completed

Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults

Pneumococcal Vaccines

United States
Zhejiang Clover Biopharmaceuticals, Inc.

Active, not recruiting

Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China

COVID-19

China
National Institute of Allergy and Infectious Diseases...

Recruiting

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

Chronic HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

Human Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus Prevention

United States
Lumos Pharma

Active, not recruiting

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) (OraGrowtH213)

Growth Hormone Deficiency

United States, Poland
Lumos Pharma

Active, not recruiting

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) (OraGrowtH212)

Growth Hormone Deficiency

Chile
Lumos Pharma

Enrolling by invitation

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211) (OraGrowtH211)

Growth Hormone Deficiency

United States, Australia
GlaxoSmithKline

Active, not recruiting

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Herpes Simplex

Germany, United States, Belgium, Canada, Spain, United Kingdom, Estonia, Australia
Clover Biopharmaceuticals AUS Pty Ltd

Recruiting

First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults

Respiratory Syncytial Virus Infection

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Recombinant Influenza Vaccine Containing Different H3 Antigens in Healthy Adults 18 to 30 Years of Age (FBP00001)

Influenza

United States
University of Oslo

Not yet recruiting

Early Intervention Coping Kids (TIM) Follow up Study (FOPPT4)

Depression | Anxiety Disorders
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

Hepatitis B

Germany, United Kingdom, Belgium
Alice Chung

Not yet recruiting

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

Breast Cancer | Mastectomy; Lymphedema | Female Breast Cancer | Axilla; Breast | Tumor, Breast | Axillary Nodal Disease
Chimerix

Terminated

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease (SUSTAIN)

Cytomegalovirus Disease

United States
International AIDS Vaccine Initiative
National Institute of Allergy and Infectious Diseases (NIAID); Access to Advanced...

Not yet recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate

Hiv
PX'Therapeutics
European Commission

Completed

Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine

- HIV

United Kingdom
International AIDS Vaccine Initiative
3M; Polymun Scientific GmbH; Access to Advanced Health Institute (AAHI)

Not yet recruiting

A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

Hiv

Netherlands
Federico II University

Unknown

Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy (COVID-preg)

Infection Viral

Italy
Federico II University

Unknown

Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy. (I-COVID)

Infection Viral

Italy
Massachusetts General Hospital

Recruiting

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease

NAFLD | NASH - Nonalcoholic Steatohepatitis | Nonalcoholic Fatty Liver

United States
Merck Sharp & Dohme LLC

Completed

Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)

Dengue
UConn Health

Active, not recruiting

Sickle Cell Hemoglobinopathies and Bone Health

Sickle Cell Disease | Sickle Cell Trait

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

Healthy Volunteer

United States
Innovative Surgical Designs

Suspended

Pedicle Osteotomy for Stenosis Trial (POST)

Lumbar Spinal Stenosis | Spondylolisthesis, Grade 1 | Neurogenic Claudication

United States
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea (CJCV1-01)

Campylobacter Infection

United States
Immutep S.A.S.
SGS Aster-Cephac (CRO)

Completed

A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321

Healthy

France
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

COVID-19

Philippines
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.

Hepatocellular Carcinoma | Radiotherapy | Narrow Margin

China

Search clinical trials for: SCB-2019 with Alum adjuvant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations